youtube_live
Q3 2026 earnings • released • EPS beat +31.19% • Revenue beat +14.25%
See resultschevron_right
SNY:NASDAQ
Sanofi SA
$45.55
arrow_upward
+2.73%(+1.21) 1D
$45.40
arrow_downward
-0.33% (-0.15)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SNY...
Open
$44.50
High
$45.59
Low
$44.50
Mkt. cap
110.59B
Avg. vol.
3.84M
Volume
7.37M
Dividend
5.31%
Quarterly dividend
$0.60
Ex-dividend date
May 5, 2026
P/E ratio
23.48
52-wk high
$52.68
52-wk low
$39.07
EPS
$1.94
Beta
0.37
Shares outstanding
2.42B
No. of employees
75K
Open
$44.50
High
$45.59
Low
$44.50
Mkt. cap
110.59B
Avg. vol.
3.84M
Volume
7.37M
Dividend
5.31%
Quarterly dividend
$0.60
Ex-dividend date
May 5, 2026
P/E ratio
23.48
52-wk high
$52.68
52-wk low
$39.07
EPS
$1.94
Beta
0.37
Shares outstanding
2.42B
No. of employees
75K
News stories
From web sources and news partners
The Manila Times
·
5 hours ago
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
The Pharma Letter
·
11 hours ago
Regeneron third-quarter revenue jumps 36% as Sanofi collaboration and Eylea HD drive beat
TradingKey
·
14 hours ago
Regeneron Stock Forecast: REGN Jumps 13% as Full Dupixent Profits Kick In, With $930.46 the Next Test
Healthcare Digital
·
15 hours ago
Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000.
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOBelén Garijo | Paul Hudson
Employees74.8K
Founded1973
HeadquartersParis, Île-de-France, France
SectorPharmaceutical industry
Websitesanofi.com